Automate Your Wheel Strategy on CVRX
With Tiblio's Option Bot, you can configure your own wheel strategy including CVRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CVRX
- Rev/Share 2.1388
- Book/Share 1.8363
- PB 3.7902
- Debt/Equity 1.0443
- CurrentRatio 9.6176
- ROIC -0.5022
- MktCap 182422345.0
- FreeCF/Share -1.1074
- PFCF -6.2948
- PE -3.501
- Debt/Assets 0.4508
- DivYield 0
- ROE -0.8445
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | CVRX | JP Morgan | Neutral | Underweight | -- | $7 | May 9, 2025 |
| Upgrade | CVRX | William Blair | Market Perform | Outperform | -- | -- | Jan. 14, 2025 |
| Initiation | CVRX | Cantor Fitzgerald | -- | Overweight | -- | $14 | Sept. 10, 2024 |
News
CVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating CVRx Inc. on Behalf of CVRx Stockholders and Encourages Investors to Contact the Firm
Published: January 30, 2026 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In CVRx (CVRX) To Contact Him Directly To Discuss Their Options
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. – CVRX
Published: January 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference
Published: December 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
MINNEAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026. The Company's presentation will begin at 3:45 p.m. (PT). A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time. …
Read More
CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Negative
CVRx (CVRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
CVRx (CVRX) Surges 19.0%: Is This an Indication of Further Gains?
Published: July 17, 2025 by: Zacks Investment Research
Sentiment: Positive
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
CVRx (CVRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction
Read More
About CVRx, Inc. (CVRX)
- IPO Date 2021-06-30
- Website https://www.cvrx.com
- Industry Medical - Devices
- CEO Kevin Hykes
- Employees 206